You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCaspofungin
Accession NumberDB00520  (APRD00199)
TypeSmall Molecule
GroupsApproved
DescriptionCaspofungin (brand name Cancidas worldwide) is an antifungal drug, the first of a new class termed the echinocandins from Merck & Co., Inc. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall. Caspofungin is administered intravenously.
Structure
Thumb
Synonyms
(4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CancidasPowder, for solution50 mgIntravenousMerck Canada Inc2001-08-23Not applicableCanada
CancidasInjection, powder, lyophilized, for solution5 mg/mLIntravenousMerck Sharp & Dohme Corp.2001-01-26Not applicableUs
CancidasPowder, for solution70 mgIntravenousMerck Canada Inc2001-10-23Not applicableCanada
CancidasInjection, powder, lyophilized, for solution7 mg/mLIntravenousMerck Sharp & Dohme Corp.2001-01-26Not applicableUs
CancidasInjection, powder, for solution50 mgIntravenousMerck Sharp & Dohme Ltd2001-10-24Not applicableEu
CancidasInjection, powder, for solution70 mgIntravenousMerck Sharp & Dohme Ltd2001-10-24Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Caspofungin acetate
179463-17-3
Thumb
  • InChI Key: OGUJBRYAAJYXQP-LLXMLGLCSA-N
  • Monoisotopic Mass: 1212.68532094
  • Average Mass: 1213.417
DBSALT000020
Categories
UNIIF0XDI6ZL63
CAS number162808-62-0
WeightAverage: 1093.3131
Monoisotopic: 1092.643062196
Chemical FormulaC52H88N10O15
InChI KeyJYIKNQVWKBUSNH-OGZDCFRISA-N
InChI
InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28?,29?,30-,33-,34+,35+,36-,37+,38-,40+,41+,42+,43+,44+,45+,46+/m1/s1
IUPAC Name
N-[(3S,6S,9S,11R,15S,18S,20R,21S,24S,25S)-3-[(1R)-3-amino-1-hydroxypropyl]-21-[(2-aminoethyl)amino]-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-15-[(1R)-1-hydroxyethyl]-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0⁹,¹³]heptacosan-18-yl]-10,12-dimethyltetradecanamide
SMILES
CCC(C)CC(C)CCCCCCCCC(=O)N[[email protected]]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[[email protected]](O)[C@@H](O)C1=CC=C(O)C=C1)[[email protected]](O)CCN
Pharmacology
IndicationFor the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
Structured Indications
PharmacodynamicsCaspofungin is an antifungal drug, and belongs to a new class termed the echinocandins. It is used to treat Aspergillus and Candida infection, and works by inhibiting cell wall synthesis. Antifungals in the echinocandin class inhibit the synthesis of glucan in the cell wall, probably via the enzyme 1,3-beta glucan synthase. There is a potential for resistance development to occur, however in vitro resistance development to Caspofungin by Aspergillus species has not been studied.
Mechanism of actionCaspofungin inhibits the synthesis of beta-(1,3)-D-glucan, an essential component of the cell wall of Aspergillus species and Candida species. beta-(1,3)-D-glucan is not present in mammalian cells. The primary target is beta-(1,3)-glucan synthase.
TargetKindPharmacological actionActionsOrganismUniProt ID
1,3-beta-glucan synthase component FKS1Proteinyes
inhibitor
Aspergillus niger (strain CBS 513.88 / FGSC A1513)A2QLK4 details
Related Articles
Absorption92% tissue distribution within 36-48 hours after intravenous infusion
Volume of distributionNot Available
Protein binding97%
Metabolism

Metabolized slowly by hydrolysis and N-acetylation

Route of eliminationAfter single intravenous administration of [3H] caspofungin acetate, excretion of caspofungin and its metabolites in humans was 35% of dose in feces and 41% of dose in urine.
Half life9-11 hours
Clearance
  • 12 mL/min [After single IV administration]
ToxicitySide effects include rash, swelling, and nausea (rare)
Affected organisms
  • Aspergillis, Candida and other fungi
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Caspofungin.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Caspofungin.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Caspofungin.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Caspofungin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Caspofungin.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Caspofungin.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Caspofungin.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Caspofungin.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Caspofungin.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Caspofungin is combined with Amrinone.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Caspofungin.Approved
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Caspofungin.Approved, Investigational
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Caspofungin.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Caspofungin.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Caspofungin.Approved, Investigational
AzelnidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Caspofungin is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Barnidipine.Approved
BenidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Benidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Caspofungin is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Caspofungin.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Caspofungin.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Caspofungin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Caspofungin.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Caspofungin.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Caspofungin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Caspofungin.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Caspofungin.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Caspofungin.Approved
CaiThe risk or severity of adverse effects can be increased when Caspofungin is combined with Cai.Investigational
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Caspofungin.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Caspofungin.Approved
CarbamazepineThe serum concentration of Caspofungin can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Caspofungin.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Caspofungin.Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Caspofungin.Approved, Vet Approved
CilnidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Cilnidipine.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Caspofungin.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Cinnarizine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Caspofungin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Caspofungin.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Caspofungin.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Caspofungin.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Caspofungin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Clevidipine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Caspofungin.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Caspofungin.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Caspofungin.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Caspofungin.Approved, Nutraceutical
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Caspofungin.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Caspofungin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Caspofungin.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Caspofungin.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Caspofungin.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Caspofungin.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Caspofungin.Approved, Investigational, Vet Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Caspofungin.Approved, Investigational, Vet Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Caspofungin.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Caspofungin.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Caspofungin.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Caspofungin.Approved
DarodipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Darodipine.Experimental
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Caspofungin.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Caspofungin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Caspofungin.Approved
DexamethasoneThe serum concentration of Caspofungin can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Caspofungin.Approved, Illicit, Vet Approved
DidanosineDidanosine can cause a decrease in the absorption of Caspofungin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Caspofungin.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Caspofungin.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Caspofungin.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Caspofungin.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Caspofungin is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Caspofungin.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Caspofungin.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Caspofungin.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Caspofungin.Approved, Investigational, Vet Approved
DotarizineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Dotarizine.Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Caspofungin.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Caspofungin.Approved
EfavirenzThe serum concentration of Caspofungin can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Efonidipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Caspofungin.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Caspofungin is combined with Eperisone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Caspofungin.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Caspofungin.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Caspofungin.Approved, Vet Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Caspofungin.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Caspofungin.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Caspofungin.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Caspofungin.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Caspofungin.Approved
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Caspofungin.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Caspofungin.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Caspofungin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Fendiline.Withdrawn
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Caspofungin.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Caspofungin.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Caspofungin.Approved
FlunarizineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Flunarizine.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Caspofungin.Approved
FosphenytoinThe serum concentration of Caspofungin can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Caspofungin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Caspofungin is combined with Gallopamil.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Caspofungin.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Caspofungin.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Caspofungin.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Caspofungin.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Caspofungin.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Caspofungin.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Caspofungin.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Caspofungin.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Caspofungin.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Caspofungin.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Caspofungin.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Caspofungin.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Caspofungin.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Caspofungin.Approved, Investigational
IsradipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Isradipine.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Caspofungin.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Caspofungin.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Caspofungin.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lacidipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Caspofungin.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Caspofungin.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Caspofungin.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Caspofungin.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Caspofungin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Caspofungin.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Caspofungin.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Caspofungin.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Caspofungin.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Caspofungin.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Caspofungin.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Caspofungin is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Manidipine.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Caspofungin.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Caspofungin.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Caspofungin.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Caspofungin.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Caspofungin is combined with Mibefradil.Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Caspofungin.Approved, Illicit
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Caspofungin.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Caspofungin.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Caspofungin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Caspofungin.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Caspofungin.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Caspofungin is combined with Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Caspofungin.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Caspofungin.Approved, Vet Approved
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Caspofungin.Approved
NevirapineThe serum concentration of Caspofungin can be decreased when it is combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Caspofungin.Approved, Investigational
NiludipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimodipine.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Caspofungin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Caspofungin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Caspofungin.Approved, Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Caspofungin.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Caspofungin.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Caspofungin.Approved, Vet Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Caspofungin.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Caspofungin.Approved
PerhexilineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Perhexiline.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Caspofungin.Approved
PhenytoinThe serum concentration of Caspofungin can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideCaspofungin may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Caspofungin is combined with Pinaverium.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Caspofungin.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Caspofungin.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Caspofungin.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Caspofungin.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Caspofungin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Caspofungin.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Caspofungin.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Caspofungin is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Caspofungin.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Caspofungin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Caspofungin.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Caspofungin.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Caspofungin.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Caspofungin.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Caspofungin.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Caspofungin.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Caspofungin.Approved
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Caspofungin.Approved
RifampicinThe serum concentration of Caspofungin can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Caspofungin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Caspofungin.Approved, Investigational
RisedronateThe risk or severity of adverse effects can be increased when Caspofungin is combined with Risedronate.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Caspofungin.Approved, Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Caspofungin.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Caspofungin.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Caspofungin.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Caspofungin.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Caspofungin.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Caspofungin.Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Caspofungin.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Caspofungin.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Caspofungin.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Caspofungin.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Caspofungin.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Caspofungin.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Caspofungin.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Caspofungin.Experimental
SucralfateSucralfate can cause a decrease in the absorption of Caspofungin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Caspofungin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Caspofungin.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Caspofungin.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Caspofungin.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Caspofungin.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Caspofungin.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Caspofungin.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Caspofungin.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Caspofungin.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Caspofungin.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Caspofungin.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tolfenamic Acid.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Caspofungin.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Caspofungin.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Caspofungin.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Caspofungin is combined with Tranilast.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Caspofungin.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Caspofungin.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Caspofungin.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Caspofungin.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Caspofungin.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Caspofungin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Caspofungin is combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Caspofungin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Caspofungin.Approved, Investigational
VinpocetineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Vinpocetine.Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Caspofungin.Approved
XylometazolineThe risk or severity of adverse effects can be increased when Caspofungin is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Caspofungin is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Caspofungin.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Caspofungin.Approved
Food InteractionsNot Available
References
Synthesis Reference

Johannes Ludescher, Ingolf Macher, Ole Storm, Stephan Bertel, “Process and Intermediates for the Synthesis of Caspofungin.” U.S. Patent US20080319162, issued December 25, 2008.

US20080319162
General References
  1. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. [PubMed:19724014 ]
  2. Morrison VA: Caspofungin: an overview. Expert Rev Anti Infect Ther. 2005 Oct;3(5):697-705. [PubMed:16207161 ]
  3. McCormack PL, Perry CM: Caspofungin: a review of its use in the treatment of fungal infections. Drugs. 2005;65(14):2049-68. [PubMed:16162025 ]
  4. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. [PubMed:16960253 ]
  5. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. [PubMed:16990627 ]
External Links
ATC CodesJ02AX04
AHFS Codes
  • 08:14.16
PDB EntriesNot Available
FDA labelDownload (87.9 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7566
Blood Brain Barrier-0.96
Caco-2 permeable-0.8091
P-glycoprotein substrateSubstrate0.8694
P-glycoprotein inhibitor INon-inhibitor0.9653
P-glycoprotein inhibitor IINon-inhibitor0.9174
Renal organic cation transporterNon-inhibitor0.9379
CYP450 2C9 substrateNon-substrate0.831
CYP450 2D6 substrateNon-substrate0.8166
CYP450 3A4 substrateNon-substrate0.51
CYP450 1A2 substrateNon-inhibitor0.9389
CYP450 2C9 inhibitorNon-inhibitor0.9161
CYP450 2D6 inhibitorNon-inhibitor0.8904
CYP450 2C19 inhibitorNon-inhibitor0.875
CYP450 3A4 inhibitorNon-inhibitor0.9682
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9781
Ames testNon AMES toxic0.7398
CarcinogenicityNon-carcinogens0.8315
BiodegradationNot ready biodegradable0.9683
Rat acute toxicity2.9344 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9637
hERG inhibition (predictor II)Non-inhibitor0.716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Merck and co inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, for solutionIntravenous50 mg
Injection, powder, for solutionIntravenous70 mg
Injection, powder, lyophilized, for solutionIntravenous5 mg/mL
Injection, powder, lyophilized, for solutionIntravenous7 mg/mL
Powder, for solutionIntravenous50 mg
Powder, for solutionIntravenous70 mg
Prices
Unit descriptionCostUnit
Cancidas iv 70 mg vial421.06USD vial
Cancidas iv 50 mg vial405.25USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2118757 No2002-05-142014-03-10Canada
CA2251928 No2003-06-172017-04-15Canada
US5378804 No1993-03-162013-03-16Us
US5514650 Yes1995-07-262015-07-26Us
US5952300 Yes1997-09-282017-09-28Us
US6136783 Yes1997-09-282017-09-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP0Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.367 mg/mLALOGPS
logP0.17ALOGPS
logP-4.8ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)8.75ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count18ChemAxon
Hydrogen Donor Count16ChemAxon
Polar Surface Area412.03 Å2ChemAxon
Rotatable Bond Count23ChemAxon
Refractivity278.78 m3·mol-1ChemAxon
Polarizability117.52 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentCyclic peptides
Alternative Parents
Substituents
  • Cyclic alpha peptide
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Cyclic carboximidic acid
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • 1,3-aminoalcohol
  • Tertiary amine
  • Secondary alcohol
  • Polyol
  • Lactam
  • Carboxamide group
  • 1,2-diol
  • Azacycle
  • Organoheterocyclic compound
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboximidic acid derivative
  • Carboximidic acid
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Aspergillus niger (strain CBS 513.88 / FGSC A1513)
Pharmacological action
yes
Actions
inhibitor
General Function:
1,3-beta-d-glucan synthase activity
Specific Function:
Catalytic subunit of the 1,3-beta-glucan synthase. Synthesizes 1,3-beta-glucan, a major structural component of the cell wall. Involved in cell wall synthesis, maintenance and cell wall remodeling (By similarity).
Gene Name:
fksA
Uniprot ID:
A2QLK4
Molecular Weight:
216972.8 Da
References
  1. Sucher AJ, Chahine EB, Balcer HE: Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009 Oct;43(10):1647-57. doi: 10.1345/aph.1M237. Epub 2009 Sep 1. [PubMed:19724014 ]
  2. Morrison VA: Caspofungin: an overview. Expert Rev Anti Infect Ther. 2005 Oct;3(5):697-705. [PubMed:16207161 ]
  3. McCormack PL, Perry CM: Caspofungin: a review of its use in the treatment of fungal infections. Drugs. 2005;65(14):2049-68. [PubMed:16162025 ]
  4. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, part 1. Am J Health Syst Pharm. 2006 Sep 15;63(18):1693-703. [PubMed:16960253 ]
  5. Morris MI, Villmann M: Echinocandins in the management of invasive fungal infections, Part 2. Am J Health Syst Pharm. 2006 Oct 1;63(19):1813-20. [PubMed:16990627 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Sandhu P, Lee W, Xu X, Leake BF, Yamazaki M, Stone JA, Lin JH, Pearson PG, Kim RB: Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos. 2005 May;33(5):676-82. Epub 2005 Feb 16. [PubMed:15716364 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 04:02